Regen BioPharma Inc. announced the appointment of Dr. Hinrich Gronemeyer, Dr. William S. Blaner, and Dr. Louise Purton to its scientific advisory board. These three experts in the field of retinoid biology have been recruited by Regen BioPharma Inc. in order to provide the company with the expertise necessary to accelerate Regen's differentiation therapy small molecule drug discovery platform. This platform aims to design small molecules that can induce differentiation of cancer stem cells by designing ligands to nuclear receptors involved in maintaining stem cell properties of cancer stem cells.

Dr. Hinrich Gronemeyer is a research director at the Institute of Genetics, Cellular &Molecular Biology in Strasbourg-Illkirch. Dr. Gronemeyer is a Research Director (Class 'Exceptional') of the French National Institute of Health and Medical Research and was Privatdozent at the University Karlsruhe. Dr. William S. Blaner is Professor of Nutritional Sciences at Columbia University where he studies the metabolism and actions of retinoids.

Dr. Louise Purton is Associate Professor at the St. Vincent's Institute of Medical Research at the University of Melbourne and is Co-Head of the Stem Cell Regulation Unit and an Associate Director at the Institute.